Blog
    Regulatory UpdateFor PhysiciansMarch 19, 2026

    FDA peptide compounding status and FAERS safety signals

    Review the regulatory standing of BPC-157, TB-500, and CJC-1295, plus emerging safety signals for semaglutide including NAION and pulmonary aspiration.

    This content is sourced exclusively from TruthTides clinical reference data and does not constitute medical advice.

    1. Clinical Question

    What is the current regulatory standing of commonly compounded peptides under FDA sections 503A and 503B, and what safety signals have been identified in recent post-marketing surveillance and clinical trials?

    2. Evidence Snapshot

    • Regulatory Status: Multiple peptides including BPC-157, TB-500, and Ipamorelin are currently classified as Category 2 bulk substances by the FDA as of March 2026.
    • Compounding Restrictions: Substances in Category 2 are cited for significant safety risks or immunogenicity concerns, making them ineligible for routine compounding.
    • Safety Signals: FAERS data for semaglutide identifies strong signals for gastrointestinal events and emerging signals for ocular and pulmonary complications.
    • Clinical Trial Data: High-grade evidence (Phase III) exists for semaglutide and tirzepatide regarding weight loss and cardiovascular outcomes, while other peptides like Thymosin Alpha-1 show negative results in specific indications (Sepsis).

    3. What the Research Shows

    As of March 2026, the regulatory landscape for bulk peptide substances is characterized by significant restrictions. Several peptides previously utilized in compounding pharmacy settings have been moved to Category 2 (Sept 2023). This includes BPC-157, which the FDA identifies as a significant safety risk due to immunogenicity concerns and a lack of safety data. Similarly, TB-500 is cited for immunogenicity risks and a lack of human exposure data.

    Regulatory actions have also impacted growth hormone secretagogues and related analogs. CJC-1295 was moved to Category 2 in September 2023 and had its nomination withdrawn and removed in September 2024; the FDA cites safety issues such as increased heart rate. Ipamorelin, AOD-9604, and Selank also saw their nominations withdrawn in September 2024.

    In contrast, therapeutic peptides with FDA approval, such as Semaglutide, demonstrate robust clinical trial results but increasing post-marketing safety signals. The STEP 1 trial (NCT03548935) showed a 14.9% weight loss, and the SELECT trial (NCT03574597) demonstrated a 20% MACE reduction. However, FAERS data through 2023 Includes 187,757 GLP-1 RA reports. Strong signals are noted for nausea, vomiting, and delayed gastric emptying. Emerging signals for semaglutide include Nonarteritic Anterior Ischemic Optic Neuropathy (NAION), with 96 cases through December 2024, and pulmonary aspiration, which was added to the Ozempic label in 2025.

    Negative clinical evidence has also emerged for certain peptides. A Phase III trial (NCT02867267) for Thymosin Alpha-1 in the treatment of sepsis showed no mortality reduction (PMID: 39814420).

    4. Mechanism

    Based on provided regulatory and trial data, the following mechanistic details are noted:

    • Semaglutide: Functions as a GLP-1 receptor agonist; its clinical effects contribute to delayed gastric emptying.
    • CJC-1295: Associated with physiological changes including increased heart rate.
    • Tesamorelin: Clinical trials for HIV lipodystrophy (NCT00451282) demonstrate a mechanism that leads to an 18% reduction in visceral adipose tissue (VAT).
    • Hepatobiliary Signals: Mechanisms of cholelithiasis and cholecystitis in semaglutide use are associated with rapid weight loss.

    5. Limitations of the Evidence

    There are significant gaps in the clinical literature for several compounds. For TB-500, the FDA explicitly notes a lack of human exposure data. For BPC-157, there is a noted lack of safety data. While Selank and Semax are approved in Russia (Semax specifically for stroke), they are not FDA-approved and lack 503A/503B clinical-need exemptions in the United States.

    Safety signals for Suicidal Ideation in semaglutide use are under evaluation; current data do not support a higher risk compared to background rates, but monitoring is required. The signal for NAION remains emerging and was only under formal EMA review as of January 2025.

    6. Clinical Takeaway

    Physicians should be aware that many peptides, including BPC-157, TB-500, and GHK-Cu, are currently classified by the FDA as Category 2 substances due to immunogenicity risks and safety concerns, making them ineligible for routine compounding. While approved GLP-1 RAs show significant efficacy in weight loss and cardiovascular risk reduction, emerging safety signals regarding pulmonary aspiration and NAION require clinical vigilance.

    7. Sources

    • FDA Regulatory Status Records (BPC-157, CJC-1295, TB-500, Ipamorelin, GHK-Cu, GHRP-2, Selank, Semax, AOD-9604, Thymosin Alpha-1).
    • FAERS Safety Signal Records (Semaglutide).
    • Clinical Trial Records: NCT03548935, NCT03574597, NCT04184622, NCT05024032, NCT04881706, NCT00451282, NCT02867267.

    Referenced Peptides

    bpc 157semaglutidetb 500cjc 1295thymosin alpha 1

    This content was generated from TruthTides clinical reference data. It does not constitute medical advice. Always consult a qualified healthcare provider.